255 related articles for article (PubMed ID: 8855805)
21. The clinical utility of parathyroid hormone-related peptide in the assessment of hypercalcemia.
Fritchie K; Zedek D; Grenache DG
Clin Chim Acta; 2009 Apr; 402(1-2):146-9. PubMed ID: 19168044
[TBL] [Abstract][Full Text] [Related]
22. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D.
Horwitz MJ; Tedesco MB; Sereika SM; Syed MA; Garcia-Ocaña A; Bisello A; Hollis BW; Rosen CJ; Wysolmerski JJ; Dann P; Gundberg C; Stewart AF
J Bone Miner Res; 2005 Oct; 20(10):1792-803. PubMed ID: 16160737
[TBL] [Abstract][Full Text] [Related]
23. Parathyroid hormone/parathyroid hormone-related peptide type 1 receptor in human bone.
Langub MC; Monier-Faugere MC; Qi Q; Geng Z; Koszewski NJ; Malluche HH
J Bone Miner Res; 2001 Mar; 16(3):448-56. PubMed ID: 11277262
[TBL] [Abstract][Full Text] [Related]
24. Receptors for PTH and PTHrP: their biological importance and functional properties.
Mannstadt M; Jüppner H; Gardella TJ
Am J Physiol; 1999 Nov; 277(5):F665-75. PubMed ID: 10564229
[TBL] [Abstract][Full Text] [Related]
25. Actions of parathyroid hormone and parathyroid hormone-related protein.
Rizzoli R; Ferrari SL; Pizurki L; Caverzasio J; Bonjour JP
J Endocrinol Invest; 1992; 15(9 Suppl 6):51-6. PubMed ID: 1338636
[TBL] [Abstract][Full Text] [Related]
26. Parathyroid hormone (PTH)/PTH-related protein receptor messenger ribonucleic acid expression and PTH response in a rat model of secondary hyperparathyroidism associated with vitamin D deficiency.
Turner G; Coureau C; Rabin MR; Escoubet B; Hruby M; Walrant O; Silve C
Endocrinology; 1995 Sep; 136(9):3751-8. PubMed ID: 7649081
[TBL] [Abstract][Full Text] [Related]
27. The parathyroid hormone (PTH)/PTH-related peptide receptor mediates actions of both ligands in murine bone.
Lanske B; Divieti P; Kovacs CS; Pirro A; Landis WJ; Krane SM; Bringhurst FR; Kronenberg HM
Endocrinology; 1998 Dec; 139(12):5194-204. PubMed ID: 9832460
[TBL] [Abstract][Full Text] [Related]
28. Laboratory screening for hyperparathyroidism.
Younes NA; Shafagoj Y; Khatib F; Ababneh M
Clin Chim Acta; 2005 Mar; 353(1-2):1-12. PubMed ID: 15698586
[TBL] [Abstract][Full Text] [Related]
29. Renal mRNA of PTH-PTHrP receptor, [Ca2+]i and phosphaturic response to PTH in phosphate depletion.
Marcinkowski W; Smogorzewski M; Zhang G; Ni Z; Kedes L; Massry SG
Miner Electrolyte Metab; 1997; 23(1):48-57. PubMed ID: 9058370
[TBL] [Abstract][Full Text] [Related]
30. Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone.
Park-Sigal J; Don BR; Porzig A; Recker R; Griswold V; Sebastian A; Duh QY; Portale AA; Shoback D; Schambelan M
J Bone Miner Res; 2013 Mar; 28(3):700-8. PubMed ID: 23074096
[TBL] [Abstract][Full Text] [Related]
31. Role of bone and kidney in parathyroid hormone-related peptide-induced hypercalcemia in rats.
Rizzoli R; Caverzasio J; Chapuy MC; Martin TJ; Bonjour JP
J Bone Miner Res; 1989 Oct; 4(5):759-65. PubMed ID: 2554691
[TBL] [Abstract][Full Text] [Related]
32. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
33. Preoperative normal level of parathyroid hormone signifies an early and mild form of primary hyperparathyroidism.
Bergenfelz A; Lindblom P; Lindergård B; Valdemarsson S; Westerdahl J
World J Surg; 2003 Apr; 27(4):481-5. PubMed ID: 12658497
[TBL] [Abstract][Full Text] [Related]
34. An update on the discovery, pathophysiological actions, clinical manifestations and possible physiology of parathyroid related peptide.
Alcantara A; Montalvo-Figueroa JA; Toro S; Aguilo F
P R Health Sci J; 1997 Mar; 16(1):15-22. PubMed ID: 9160398
[TBL] [Abstract][Full Text] [Related]
35. Primary hyperparathyroidism and parathyroid hormone-related protein.
Horwitz MJ; Bilezikian JP
Curr Opin Rheumatol; 1994 May; 6(3):321-8. PubMed ID: 8060769
[TBL] [Abstract][Full Text] [Related]
36. Familial hypocalciuric hypercalcemia caused by an R648stop mutation in the calcium-sensing receptor gene.
Yamauchi M; Sugimoto T; Yamaguchi T; Yano S; Wang J; Bai M; Brown EM; Chihara K
J Bone Miner Res; 2002 Dec; 17(12):2174-82. PubMed ID: 12469911
[TBL] [Abstract][Full Text] [Related]
37. [Hypercalcemia is the most common manifestation of hyperparathyroidism].
Yuzawa Y; Watanabe Y
Nihon Rinsho; 1995 Apr; 53(4):864-9. PubMed ID: 7752474
[TBL] [Abstract][Full Text] [Related]
38. Immunoassays for parathyroid hormone 1-84 in the diagnosis of hyperparathyroidism.
Nussbaum SR; Potts JT
J Bone Miner Res; 1991 Oct; 6 Suppl 2():S43-50; discussion S61. PubMed ID: 1722383
[TBL] [Abstract][Full Text] [Related]
39. In vivo studies of parathyroid gland function in secondary hyperparathyroidism.
Salusky IB; Goodman WG
Adv Nephrol Necker Hosp; 1996; 25():289-302. PubMed ID: 8717632
[TBL] [Abstract][Full Text] [Related]
40. Clodronate in the medical management of hyperparathyroidism.
Hamdy NA; Gray RE; McCloskey E; Galloway J; Rattenbury JM; Brown CB; Kanis JA
Bone; 1987; 8 Suppl 1():S69-77. PubMed ID: 2961358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
